Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...
CagriSema could still be a commercial success, though ... For one, semaglutide, the active ingredient in Wegovy, is being investigated in other areas with high unmet needs. Perhaps the best ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback